Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000.
Identifieur interne : 008E94 ( Main/Exploration ); précédent : 008E93; suivant : 008E95Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000.
Auteurs : Steven I. Mclaughlin [États-Unis] ; Jeanne Radday ; Marie Carmel Michel ; David G. Addiss ; Michael J. Beach ; Patrick J. Lammie ; John Lammie ; Richard Rheingans ; Jack LafontantSource :
- The American journal of tropical medicine and hygiene [ 0002-9637 ] ; 2003.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Albendazole (effets indésirables), Albendazole (usage thérapeutique), Albendazole (économie), Antihelminthiques (effets indésirables), Antihelminthiques (usage thérapeutique), Antihelminthiques (économie), Coûts des soins de santé, Diéthylcarbamazine (effets indésirables), Diéthylcarbamazine (usage thérapeutique), Diéthylcarbamazine (économie), Facteurs de l'âge, Facteurs sexuels, Femelle, Filaricides (effets indésirables), Filaricides (usage thérapeutique), Filaricides (économie), Filariose lymphatique (traitement médicamenteux), Filariose lymphatique (économie), Haïti, Humains, Mâle.
- MESH :
- effets indésirables : Albendazole, Antihelminthiques, Diéthylcarbamazine, Filaricides.
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Albendazole, Antihelminthiques, Diéthylcarbamazine, Filaricides.
- économie : Albendazole, Antihelminthiques, Diéthylcarbamazine, Filaricides, Filariose lymphatique.
- Adolescent, Adulte, Adulte d'âge moyen, Coûts des soins de santé, Facteurs de l'âge, Facteurs sexuels, Femelle, Haïti, Humains, Mâle.
- Wicri :
- geographic : Haïti.
English descriptors
- KwdEn :
- Adolescent, Adult, Age Factors, Albendazole (adverse effects), Albendazole (economics), Albendazole (therapeutic use), Anthelmintics (adverse effects), Anthelmintics (economics), Anthelmintics (therapeutic use), Diethylcarbamazine (adverse effects), Diethylcarbamazine (economics), Diethylcarbamazine (therapeutic use), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (economics), Female, Filaricides (adverse effects), Filaricides (economics), Filaricides (therapeutic use), Haiti, Health Care Costs, Humans, Male, Middle Aged, Sex Factors.
- MESH :
- chemical , adverse effects : Albendazole, Anthelmintics, Diethylcarbamazine, Filaricides.
- chemical , economics : Albendazole, Anthelmintics, Diethylcarbamazine, Filaricides.
- chemical , therapeutic use : Albendazole, Anthelmintics, Diethylcarbamazine, Filaricides.
- geographic : Haiti.
- drug therapy : Elephantiasis, Filarial.
- economics : Elephantiasis, Filarial.
- Adolescent, Adult, Age Factors, Female, Health Care Costs, Humans, Male, Middle Aged, Sex Factors.
Abstract
In October 2000, 71,187 persons were treated for lymphatic filariasis using albendazole and diethylcarbamazine (DEC) or DEC alone in Leogane, Haiti. We documented the frequency of adverse reactions, severity and cost of treatment. Adverse reactions were classified as minor, moderate, or severe. Overall, 24% (17,421) of the treated persons reported one or more adverse reactions. There were 15,916 (91%) minor and 1502 (9%) moderate adverse reaction reports. Men outnumbered women 2:1 in reporting moderate problems. Three patients, representing roughly one in 25,000 persons treated, were hospitalized with severe adverse reactions judged to be treatment-associated by physician review. The cost per person treated for adverse reactions was more than twice the cost per person treated for lymphatic filariasis (dollar 1.60 versus dollar 0.71). Severe adverse reactions to lymphatic filariasis treatment using DEC with or without albendazole are uncommon. Minor and moderate reactions are more commonly reported and their management represents a challenge to lymphatic filariasis elimination programs.
PubMed: 12812348
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004238
- to stream PubMed, to step Curation: 004238
- to stream PubMed, to step Checkpoint: 004238
- to stream Ncbi, to step Merge: 000D83
- to stream Ncbi, to step Curation: 000D83
- to stream Ncbi, to step Checkpoint: 000D83
- to stream Main, to step Merge: 009187
- to stream Main, to step Curation: 008E94
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000.</title><author><name sortKey="Mclaughlin, Steven I" sort="Mclaughlin, Steven I" uniqKey="Mclaughlin S" first="Steven I" last="Mclaughlin">Steven I. Mclaughlin</name><affiliation wicri:level="1"><nlm:affiliation>Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. swm4@cdc.gov</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333</wicri:regionArea><wicri:noRegion>Georgia 30333</wicri:noRegion></affiliation></author><author><name sortKey="Radday, Jeanne" sort="Radday, Jeanne" uniqKey="Radday J" first="Jeanne" last="Radday">Jeanne Radday</name></author><author><name sortKey="Michel, Marie Carmel" sort="Michel, Marie Carmel" uniqKey="Michel M" first="Marie Carmel" last="Michel">Marie Carmel Michel</name></author><author><name sortKey="Addiss, David G" sort="Addiss, David G" uniqKey="Addiss D" first="David G" last="Addiss">David G. Addiss</name></author><author><name sortKey="Beach, Michael J" sort="Beach, Michael J" uniqKey="Beach M" first="Michael J" last="Beach">Michael J. Beach</name></author><author><name sortKey="Lammie, Patrick J" sort="Lammie, Patrick J" uniqKey="Lammie P" first="Patrick J" last="Lammie">Patrick J. Lammie</name></author><author><name sortKey="Lammie, John" sort="Lammie, John" uniqKey="Lammie J" first="John" last="Lammie">John Lammie</name></author><author><name sortKey="Rheingans, Richard" sort="Rheingans, Richard" uniqKey="Rheingans R" first="Richard" last="Rheingans">Richard Rheingans</name></author><author><name sortKey="Lafontant, Jack" sort="Lafontant, Jack" uniqKey="Lafontant J" first="Jack" last="Lafontant">Jack Lafontant</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:12812348</idno><idno type="pmid">12812348</idno><idno type="wicri:Area/PubMed/Corpus">004238</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004238</idno><idno type="wicri:Area/PubMed/Curation">004238</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004238</idno><idno type="wicri:Area/PubMed/Checkpoint">004238</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">004238</idno><idno type="wicri:Area/Ncbi/Merge">000D83</idno><idno type="wicri:Area/Ncbi/Curation">000D83</idno><idno type="wicri:Area/Ncbi/Checkpoint">000D83</idno><idno type="wicri:doubleKey">0002-9637:2003:Mclaughlin S:frequency:severity:and</idno><idno type="wicri:Area/Main/Merge">009187</idno><idno type="wicri:Area/Main/Curation">008E94</idno><idno type="wicri:Area/Main/Exploration">008E94</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000.</title><author><name sortKey="Mclaughlin, Steven I" sort="Mclaughlin, Steven I" uniqKey="Mclaughlin S" first="Steven I" last="Mclaughlin">Steven I. Mclaughlin</name><affiliation wicri:level="1"><nlm:affiliation>Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. swm4@cdc.gov</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333</wicri:regionArea><wicri:noRegion>Georgia 30333</wicri:noRegion></affiliation></author><author><name sortKey="Radday, Jeanne" sort="Radday, Jeanne" uniqKey="Radday J" first="Jeanne" last="Radday">Jeanne Radday</name></author><author><name sortKey="Michel, Marie Carmel" sort="Michel, Marie Carmel" uniqKey="Michel M" first="Marie Carmel" last="Michel">Marie Carmel Michel</name></author><author><name sortKey="Addiss, David G" sort="Addiss, David G" uniqKey="Addiss D" first="David G" last="Addiss">David G. Addiss</name></author><author><name sortKey="Beach, Michael J" sort="Beach, Michael J" uniqKey="Beach M" first="Michael J" last="Beach">Michael J. Beach</name></author><author><name sortKey="Lammie, Patrick J" sort="Lammie, Patrick J" uniqKey="Lammie P" first="Patrick J" last="Lammie">Patrick J. Lammie</name></author><author><name sortKey="Lammie, John" sort="Lammie, John" uniqKey="Lammie J" first="John" last="Lammie">John Lammie</name></author><author><name sortKey="Rheingans, Richard" sort="Rheingans, Richard" uniqKey="Rheingans R" first="Richard" last="Rheingans">Richard Rheingans</name></author><author><name sortKey="Lafontant, Jack" sort="Lafontant, Jack" uniqKey="Lafontant J" first="Jack" last="Lafontant">Jack Lafontant</name></author></analytic><series><title level="j">The American journal of tropical medicine and hygiene</title><idno type="ISSN">0002-9637</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Factors</term><term>Albendazole (adverse effects)</term><term>Albendazole (economics)</term><term>Albendazole (therapeutic use)</term><term>Anthelmintics (adverse effects)</term><term>Anthelmintics (economics)</term><term>Anthelmintics (therapeutic use)</term><term>Diethylcarbamazine (adverse effects)</term><term>Diethylcarbamazine (economics)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (economics)</term><term>Female</term><term>Filaricides (adverse effects)</term><term>Filaricides (economics)</term><term>Filaricides (therapeutic use)</term><term>Haiti</term><term>Health Care Costs</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Sex Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Albendazole (effets indésirables)</term><term>Albendazole (usage thérapeutique)</term><term>Albendazole (économie)</term><term>Antihelminthiques (effets indésirables)</term><term>Antihelminthiques (usage thérapeutique)</term><term>Antihelminthiques (économie)</term><term>Coûts des soins de santé</term><term>Diéthylcarbamazine (effets indésirables)</term><term>Diéthylcarbamazine (usage thérapeutique)</term><term>Diéthylcarbamazine (économie)</term><term>Facteurs de l'âge</term><term>Facteurs sexuels</term><term>Femelle</term><term>Filaricides (effets indésirables)</term><term>Filaricides (usage thérapeutique)</term><term>Filaricides (économie)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Filariose lymphatique (économie)</term><term>Haïti</term><term>Humains</term><term>Mâle</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Haiti</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Albendazole</term><term>Antihelminthiques</term><term>Diéthylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term><term>Antihelminthiques</term><term>Diéthylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Albendazole</term><term>Antihelminthiques</term><term>Diéthylcarbamazine</term><term>Filaricides</term><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Factors</term><term>Female</term><term>Health Care Costs</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Sex Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Coûts des soins de santé</term><term>Facteurs de l'âge</term><term>Facteurs sexuels</term><term>Femelle</term><term>Haïti</term><term>Humains</term><term>Mâle</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Haïti</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In October 2000, 71,187 persons were treated for lymphatic filariasis using albendazole and diethylcarbamazine (DEC) or DEC alone in Leogane, Haiti. We documented the frequency of adverse reactions, severity and cost of treatment. Adverse reactions were classified as minor, moderate, or severe. Overall, 24% (17,421) of the treated persons reported one or more adverse reactions. There were 15,916 (91%) minor and 1502 (9%) moderate adverse reaction reports. Men outnumbered women 2:1 in reporting moderate problems. Three patients, representing roughly one in 25,000 persons treated, were hospitalized with severe adverse reactions judged to be treatment-associated by physician review. The cost per person treated for adverse reactions was more than twice the cost per person treated for lymphatic filariasis (dollar 1.60 versus dollar 0.71). Severe adverse reactions to lymphatic filariasis treatment using DEC with or without albendazole are uncommon. Minor and moderate reactions are more commonly reported and their management represents a challenge to lymphatic filariasis elimination programs.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Addiss, David G" sort="Addiss, David G" uniqKey="Addiss D" first="David G" last="Addiss">David G. Addiss</name><name sortKey="Beach, Michael J" sort="Beach, Michael J" uniqKey="Beach M" first="Michael J" last="Beach">Michael J. Beach</name><name sortKey="Lafontant, Jack" sort="Lafontant, Jack" uniqKey="Lafontant J" first="Jack" last="Lafontant">Jack Lafontant</name><name sortKey="Lammie, John" sort="Lammie, John" uniqKey="Lammie J" first="John" last="Lammie">John Lammie</name><name sortKey="Lammie, Patrick J" sort="Lammie, Patrick J" uniqKey="Lammie P" first="Patrick J" last="Lammie">Patrick J. Lammie</name><name sortKey="Michel, Marie Carmel" sort="Michel, Marie Carmel" uniqKey="Michel M" first="Marie Carmel" last="Michel">Marie Carmel Michel</name><name sortKey="Radday, Jeanne" sort="Radday, Jeanne" uniqKey="Radday J" first="Jeanne" last="Radday">Jeanne Radday</name><name sortKey="Rheingans, Richard" sort="Rheingans, Richard" uniqKey="Rheingans R" first="Richard" last="Rheingans">Richard Rheingans</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Mclaughlin, Steven I" sort="Mclaughlin, Steven I" uniqKey="Mclaughlin S" first="Steven I" last="Mclaughlin">Steven I. Mclaughlin</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008E94 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008E94 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:12812348
|texte= Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:12812348" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |